Amivantamab, a bispecific antibody targeting EGFR and MET, was recently approved by the FDA to treat NSCLC patients and it has demonstrated exciting potential in treating MET-aberrant patients according to the CHRYSALIS study (Park et al., 2021). This evidence concerns the gene EGFR and non-small cell lung carcinoma.